Lodelcizumab, a recently developed monoclonal antigen, represents a promising alternative in the effort against chronic migraines. Unlike many existing therapies that focus pain immediately, lodelcizumab specifically inhibits CGRP, a important protein associated in migraine generation. This disti… Read More
Idactamab INT-001 represents a interesting therapeutic strategy for treating certain oncological cancers. This particular antigen-binding protein is the special mechanism of action, particularly binding to CD38, the cell-surface molecule found often on several blood-forming cells. Ongoing clinica… Read More
The introduction of troglitazone, a potent antidiabetic agent, marked a notable chapter in the control of type 2 diabetes. However, its withdrawal from the market due to serious hepatotoxicity spurred broad investigation into related thiazolidinediones. Following pioglitazone and rosiglitazone em… Read More